CARDIOME PHARMA CORP  

(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
9.51
+0.51 (5.67%)
Sep 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.88 - 9.57
52 week 6.56 - 11.31
Open 8.99
Vol / Avg. 22,097.00/36,465.00
Mkt cap 154.72M
P/E     -
Div/yield     -
EPS -1.32
Shares 17.24M
Beta 1.59
Inst. own 271%
Nov 5, 2015
Q3 2015 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Cardiome Pharma Corp at Rodman & Renshaw Global Investment Conference - 11:40AM EDT - Add to calendar
Aug 12, 2015
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 5, 2015
Q2 2015 Cardiome Pharma Corp Earnings Call
Aug 5, 2015
Q2 2015 Cardiome Pharma Corp Earnings Release
Jun 16, 2015
Cardiome Pharma Corp Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -128.29% -60.67%
Operating margin -129.40% -55.21%
EBITD margin - -48.05%
Return on average assets -70.44% -37.41%
Return on average equity -243.23% -91.63%
Employees 85 -
CDP Score - -

Address

1441 Creekside Dr 6th Floor
VANCOUVER, BC V6J 4S7
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed, in-hospital, cardiology products, BRINAVESSTM and AGGRASTAT, which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)), is approved in the European Union, and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.

Officers and directors

W. James O'Shea Chairman of the Board
Bio & Compensation  - Reuters
William L. Hunter M.D., President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Jennifer Archibald Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
David D. McMasters J.D. General Counsel
Bio & Compensation  - Reuters
Richard M. Glickman L.L.D Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Arthur H. Willms Director
Age: 73
Bio & Compensation  - Reuters
Peter W Roberts CPA Independent Director
Bio & Compensation  - Reuters
Harold H. Shlevin M.D., Ph.D Independent Director
Age: 65
Bio & Compensation  - Reuters